By Diagnostics World Staff
January 21, 2020 | Qlucore, a developer of bioinformatics software, is expanding into the area of precision medicine and precision diagnostics. In order to finance the expansion, Qlucore has recently finalized a rights issue of 400k Euros and is pleased to announce two new members of the Board.
Qlucore has created a software platform for precision medicine and diagnostics, building on the development and success of Qlucore Omics Explorer which is now used by researchers in more than 35 countries. The first generation of the new software platform supports analysis and visualization of so-called fusion genes that play important roles in the diagnosis and treatment of cancer forms, such as acute lymphoblastic leukemia and non-small cell lung cancer. Future versions will include classifiers that will assist physicians and pathologists to classify a sample in subgroups using gene expression signatures.
Qlucore’s software uses powerful statistical methods to interactively explore and analyze multivariate data sets, from small to very large, as well as data generated with NGS technologies.
Increasingly data generated with NGS technologies is being used in clinical settings. “It is a natural development that the data that our research customers have worked with using Qlucore Omics Explorer for several years is now ready to be moved into clinical use. The lack of software solutions is apparent and with our experience we will fill that gap”, says Carl-Johan Ivarsson, Qlucore President.
Alongside the move into precision medicine and diagnostics comes a rights issue of 400k Euros and the appointment of Johan Thiel and Boel Sundvall to the Board.
Boel has an MSc in Business and Economics from the Stockholm School of Economics and has held senior management positions in several companies listed in Sweden. She has broad experience from several industries, with a background in Finance, Corporate Finance, Investor Relations and Communications.
Johan Thiel is an entrepreneur with a passion for building business and creating value, and for the past six years has been a CEO focusing on Sales and Marketing, Manufacturing and Product Development.